QQ客服 官方微博 反馈留言

	All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china
	Gong, Guozhong; Wei, Lai; Xu, Xiaoyuan; Guan, Yujuan; Zheng, Sujun; Sheng, Ji-Fang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi
刊名	JOURNAL OF HEPATOLOGY
	2019
卷号	70
ISSN号	0168-8278
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3534669
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Gong, Guozhong,Wei, Lai,Xu, Xiaoyuan,et al. All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china[J]. JOURNAL OF HEPATOLOGY,2019,70.
APA	Gong, Guozhong.,Wei, Lai.,Xu, Xiaoyuan.,Guan, Yujuan.,Zheng, Sujun.,...&Wu, Jinzi.(2019).All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china.JOURNAL OF HEPATOLOGY,70.
MLA	Gong, Guozhong,et al."All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china".JOURNAL OF HEPATOLOGY 70(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。